202 related articles for article (PubMed ID: 9610594)
1. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A
Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594
[TBL] [Abstract][Full Text] [Related]
2. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Steele J; Webster C; Donohue M; Solc Z; Huff W; Cantor A
J Endourol; 2000 May; 14(4):343-50. PubMed ID: 10910150
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
4. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
8. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
9. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
10. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
[TBL] [Abstract][Full Text] [Related]
11. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
12. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
13. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M
Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation.
Stone NN; Stock RG
Tech Urol; 1995; 1(2):72-80. PubMed ID: 9118374
[TBL] [Abstract][Full Text] [Related]
15. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
Stock RG; Berkowitz J; Blacksburg SR; Stone NN
BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
[TBL] [Abstract][Full Text] [Related]
16. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Stone NN; Stock RG; Unger P
Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
[TBL] [Abstract][Full Text] [Related]
17. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
18. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.
Whittington R; Broderick GA; Arger P; Malkowicz SB; Epperson RD; Arjomandy B; Kassaee A
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1107-10. PubMed ID: 10421544
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Urology; 2002 Jul; 60(1):98-103. PubMed ID: 12100932
[TBL] [Abstract][Full Text] [Related]
20. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer.
Stone NN; Stock RG; Unger P; Kao J
J Endourol; 2000 May; 14(4):375-80. PubMed ID: 10910155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
